Cargando…

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring

BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failur...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Wyl, Viktor, Cambiano, Valentina, Jordan, Michael R., Bertagnolio, Silvia, Miners, Alec, Pillay, Deenan, Lundgren, Jens, Phillips, Andrew N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414499/ https://www.ncbi.nlm.nih.gov/pubmed/22905175 http://dx.doi.org/10.1371/journal.pone.0042834

Ejemplares similares

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings
por: Phillips, Andrew, et al.
Publicado: (2014)

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2017)

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
por: Pierre, Samuel, et al.
Publicado: (2021)

Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
por: Huntington, Susie, et al.
Publicado: (2014)

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
por: Ross, L. L., et al.
Publicado: (2010)

Projected Lifetime Healthcare Costs Associated with HIV Infection
por: Nakagawa, Fumiyo, et al.
Publicado: (2015)

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort
por: Scarsi, Kimberly K., et al.
Publicado: (2016)

Comparison of Tenofovir, Zidovudine, or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-Limited-Setting: A Cohort Study
por: Velen, Kavindhran, et al.
Publicado: (2013)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM
por: Phillips, Andrew N., et al.
Publicado: (2015)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir
por: Vivanti, Alexandre, et al.
Publicado: (2015)

Zidovudine.
por: Sperling, R
Publicado: (1998)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults
por: Badii, Vitus Sambo, et al.
Publicado: (2018)

Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries
por: Cambiano, Valentina, et al.
Publicado: (2015)

Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine
por: Ray, Shilpa, et al.
Publicado: (2020)

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis
por: Gupta, Ravindra K, et al.
Publicado: (2012)

Hair Zidovudine Concentrations Predict Virologic Outcomes Among People Living with HIV/AIDS in China
por: Wu, Yan, et al.
Publicado: (2022)

Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic
por: Phillips, Andrew N., et al.
Publicado: (2013)

Preferences for HIV testing services among men who have sex with men in the UK: A discrete choice experiment
por: Miners, Alec, et al.
Publicado: (2019)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Zidovudine-induced myopathy
por: Wiwanitkit, Viroj
Publicado: (2011)

Zidovudine Induced Hyperpigmentation
por: Premjith, Raveendran, et al.
Publicado: (2022)

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis
por: Dadi, Tegene Legese, et al.
Publicado: (2017)

Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2017)

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2017)

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer
por: Schneider, Marcel A., et al.
Publicado: (2021)

Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS
por: Renner, Lorna A, et al.
Publicado: (2013)

Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts
por: Ouattara, Eric, et al.
Publicado: (2013)

Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health
por: Kinai, Ei, et al.
Publicado: (2021)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings
por: Kiragga, Agnes N, et al.
Publicado: (2010)

INCIDENCE OF ANAEMIA AMONG HIV-INFECTED PATIENTS TREATED WITH ZIDOVUDINE-CONTAINING ANTIRETROVIRAL THERAPY IN NORTHEASTERN NIGERIA
por: Ikunaiye, N.Y., et al.
Publicado: (2018)

To study the incidence of anemia in HIV-infected children on zidovudine-based highly active antiretroviral therapy regimen
por: Maurya, Manisha, et al.
Publicado: (2020)

Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study
por: Labhardt, Niklaus Daniel, et al.
Publicado: (2014)

Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study
por: Ayele, Teshale, et al.
Publicado: (2017)

Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study
por: Ayele, Teshale, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oq71uv8mo409jl3g2ud99l0afk